サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1712728

神経変性疾患治療薬の世界市場レポート 2025年

Neurodegenerative Disorder Therapeutics Global Market Report 2025

出版日
ページ情報
英文 250 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
神経変性疾患治療薬の世界市場レポート 2025年
出版日: 2025年04月09日
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経変性疾患治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.0％で283億3,000万米ドルに成長します。予測期間の成長は、個別化医療、標的治療、臨床試験の利用可能性の増加、ヘルスケア支出の増加に対する需要の高まりに起因しています。予測期間における主な動向には、疾患修飾療法、非薬理学的介入、遠隔医療と遠隔モニタリング、技術革新、精密治療、デジタルヘルスソリューション、バイオマーカー主導型臨床試験などがあります。

神経変性疾患の世界の発生拡大は、神経変性疾患治療薬市場の成長を促進します。神経変性疾患の増加は、高齢者人口の増加と密接に関連しています。World Population Prospectsによると、60歳以上の高齢者は2050年までに21億人に達し、80歳以上の高齢者は3倍の4億2,500万人に達します。アルツハイマー病協会の報告によると、現在、約580万人のアメリカ人がアルツハイマー病を患っており、2050年には約1,400万人に急増すると予測されています。このような高齢化社会における有病率の増加は、治療薬に対する需要を高め、結果として神経変性疾患治療薬市場を促進しています。

神経変性疾患をターゲットとした治療薬の研究開発（R&D）への投資が増加していることが、今後の神経変性疾患治療薬市場の成長を促進すると予想されます。政府や組織は、これらの疾患の有病率の増加、重大なアンメット・メディカル・ニーズ、経済的意味合い、世界・ヘルスへの取り組みなど、いくつかの説得力のある理由からこれらの投資に着手しています。例えば、2023年3月、カナダに本部を置く連邦政府であるカナダ政府は、神経変性疾患に関する調査を推進することを目的とした3,830万米ドルの投資を発表しました。その結果、神経変性疾患治療薬の研究開発への投資の増加は、予測期間中、この市場の成長を引き続き促進すると思われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界神経変性疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の神経変性疾患治療薬市場：成長率分析
  • 世界の神経変性疾患治療薬市場の実績：規模と成長, 2019-2024
  • 世界の神経変性疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
  • 世界神経変性疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の神経変性疾患治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • パーキンソン病
  • アルツハイマー病
  • 多発性硬化症
  • ハンチントン病
  • その他の適応症の種類
  • 世界の神経変性疾患治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • N-メチル-D-アスパラギン酸受容体
  • 選択的セロトニン再取り込み阻害薬
  • ドーパミン阻害剤
  • その他の薬物の種類
  • 世界の神経変性疾患治療薬市場配布先別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の神経変性疾患治療薬市場パーキンソン病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ドーパミン作動薬
  • MAO-B阻害剤
  • COMT阻害剤
  • 抗コリン薬
  • 世界の神経変性疾患治療薬市場アルツハイマー病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • コリンエステラーゼ阻害剤
  • NMDA受容体拮抗薬
  • 抗アミロイドモノクローナル抗体
  • 世界の神経変性疾患治療薬市場多発性硬化症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 免疫調節薬
  • 免疫抑制剤
  • コルチコステロイド
  • 世界の神経変性疾患治療薬市場ハンチントン病の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • テトラベナジン
  • 抗精神病薬
  • 世界の神経変性疾患治療薬市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 筋萎縮性側索硬化症（ALS）の治療
  • 前頭側頭型認知症の治療
  • プリオン病の治療

第7章 地域別・国別分析

  • 世界の神経変性疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の神経変性疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経変性疾患治療薬市場：競合情勢
  • 神経変性疾患治療薬市場：企業プロファイル
    • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • UCB S.A.
  • F. Hoffmann-La Roche Ltd.
  • ACADIA Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Boehringer Ingelheim International GmbH
  • Merck Serono S.A.
  • Orion Corporation
  • Mitsubishi Tanabe Pharma America
  • Allergan PLC
  • GlaxoSmithKline PLC
  • AbbVie Inc.
  • Eli Lilly and Company
  • Celgene Corporation
  • Neuro-Hitech Inc.
  • Bayer Schering Pharma AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 神経変性疾患治療薬市場2029：新たな機会を提供する国
  • 神経変性疾患治療薬市場2029：新たな機会を提供するセグメント
  • 神経変性疾患治療薬市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r32939

Neurodegenerative disorder therapeutics encompass medications or gene therapies designed to therapeutically address patients with neurodegenerative disorders. These aim to directly address underlying disease pathways, focusing on neuroprotection, neurorestoration, and managing symptoms.

The primary drug categories within neurodegenerative disorder therapeutics include N-methyl-D-aspartate receptor drugs, selective serotonin reuptake inhibitors, dopamine inhibitors, and other classes. Selective serotonin reuptake inhibitors, commonly used in treating depression and certain mental illnesses, have diverse applications across conditions such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and other related indications. These medications are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $20.04 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, rising prevalence of neurodegenerative disorders, increasing life expectancy, rising investments from pharmaceutical companies, awareness and advocacy.

The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $28.33 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rising demand for personalized medicine, targeted therapy, increasing availability of clinical trials, rising healthcare expenditure. Major trends in the forecast period include disease-modifying therapies, non-pharmacological interventions, telemedicine and remote monitoring, technological innovations, precision therapeutics, digital health solutions, biomarker-driven trials.

The expanding occurrence of neurodegenerative disorders globally drives the growth of the market for neurodegenerative disorder therapeutics. The rise in neurodegenerative conditions is closely linked to the increasing elderly population. As per World Population Prospects, the elderly, aged 60 and above, will reach 2.1 billion by 2050, with the number of individuals over 80 years old tripling to 425 million. Reports from the Alzheimer's Association reveal that currently, around 5.8 million Americans suffer from Alzheimer's disease, projected to surge to approximately 14 million by 2050. This heightened prevalence within aging demographics elevates the demand for therapeutics, consequently propelling the neurodegenerative disorder therapeutics market.

The rising investment in research and development (R&D) for therapeutics targeting neurodegenerative disorders is expected to drive the growth of the neurodegenerative disorder therapeutics market in the future. Governments and organizations are initiating these investments for several compelling reasons, including the growing prevalence of these disorders, significant unmet medical needs, economic implications, and global health initiatives, among others. For example, in March 2023, the Government of Canada, a federal administration based in Canada, announced a $38.3 million investment aimed at advancing research into neurodegenerative diseases. As a result, the increasing investment in R&D for neurodegenerative disorder therapeutics is likely to continue propelling the growth of this market during the forecast period.

Manufacturers of neurodegenerative disorder therapeutics are forging strategic partnerships with governmental and non-governmental entities to advance therapeutic solutions for various neurodegenerative diseases. Collaboration among market players is intensifying to bolster research and development capabilities, aiming to innovate new and more efficacious treatments for these disorders. For instance, in July 2022, UK-based NRG Therapeutics partnered with Domainex to jointly develop novel small molecule disease-modifying medications targeting Parkinson's disease, motor neurone disease (MND), and other chronic neurodegenerative conditions.

Key players in the neurodegenerative disorder therapeutics market are leveraging innovative techniques, such as the Neurofilament Light Chain (NfL) blood test, to gain a competitive edge. This test enables medical professionals to detect and confirm signs of neurodegenerative disorders, enhancing diagnostic accuracy and treatment planning. Labcorp, a US-based company, introduced the Neurofilament Light Chain (NfL) blood test in July 2022, allowing for direct evidence of neuronal damage. Elevated NfL levels serve as indicators of neuronal damage caused by conditions like multiple sclerosis, Alzheimer's, Parkinson's disease, or brain injuries such as concussions. NfL, a neuron-specific protein, is a non-specific biomarker for various neurodegenerative conditions like Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), released in response to neuronal injury and neurodegeneration.

In January 2022, VitalPath, a US-based manufacturer of catheters and catheter shafts acquired Modern Catheter Technologies for an undisclosed amount. The acquisition will increase VitalPath's capacity for growth, bringing its entire manufacturing footprint to more than 80,000 square feet, including 35,000 square feet of ISO 7 and 8 cleanroom space. Modern Catheter Technologies is a US-based manufacturer of microcatheters used in neurovascular and electrophysiology.

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disorder Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurodegenerative disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disorder therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurodegenerative disorder therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Indication Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Other Indication Types
  • 2) By Drug Type: N- methyl- D- aspartate Receptor; Selective Serotonin Reuptake Inhibitor; Dopamine Inhibitors; Other Drug Types
  • 3) By Distribution: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • Subsegments:
  • 1) By Parkinson's Disease: Dopamine Agonists; MAO-B Inhibitors; COMT Inhibitors; Anticholinergics
  • 2) By Alzheimer's Disease: Cholinesterase Inhibitors; NMDA Receptor Antagonists; Anti-Amyloid Monoclonal Antibodies
  • 3) By Multiple Sclerosis: Immunomodulators; Immunosuppressants; Corticosteroids
  • 4) By Huntington's Disease: Tetrabenazine; Antipsychotic Medications
  • 5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments; Frontotemporal Dementia Treatments; Prion Disease Treatments
  • Companies Mentioned: Biogen Inc.; Pfizer Inc.; Novartis International AG; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurodegenerative Disorder Therapeutics Market Characteristics

3. Neurodegenerative Disorder Therapeutics Market Trends And Strategies

4. Neurodegenerative Disorder Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurodegenerative Disorder Therapeutics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurodegenerative Disorder Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurodegenerative Disorder Therapeutics Market Growth Rate Analysis
  • 5.4. Global Neurodegenerative Disorder Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurodegenerative Disorder Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurodegenerative Disorder Therapeutics Total Addressable Market (TAM)

6. Neurodegenerative Disorder Therapeutics Market Segmentation

  • 6.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Huntington Disease
  • Other Indication Types
  • 6.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • N-methyl-D-aspartate Receptor
  • Selective Serotonin Reuptake Inhibitor
  • Dopamine Inhibitors
  • Other Drug Types
  • 6.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.4. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dopamine Agonists
  • MAO-B Inhibitors
  • COMT Inhibitors
  • Anticholinergics
  • 6.5. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Anti-Amyloid Monoclonal Antibodies
  • 6.6. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Multiple Sclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunomodulators
  • Immunosuppressants
  • Corticosteroids
  • 6.7. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tetrabenazine
  • Antipsychotic Medications
  • 6.8. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Other Indication Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amyotrophic Lateral Sclerosis (ALS) Treatments
  • Frontotemporal Dementia Treatments
  • Prion Disease Treatments

7. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

  • 7.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurodegenerative Disorder Therapeutics Market

  • 8.1. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurodegenerative Disorder Therapeutics Market

  • 9.1. China Neurodegenerative Disorder Therapeutics Market Overview
  • 9.2. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurodegenerative Disorder Therapeutics Market

  • 10.1. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurodegenerative Disorder Therapeutics Market

  • 11.1. Japan Neurodegenerative Disorder Therapeutics Market Overview
  • 11.2. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurodegenerative Disorder Therapeutics Market

  • 12.1. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurodegenerative Disorder Therapeutics Market

  • 13.1. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurodegenerative Disorder Therapeutics Market

  • 14.1. South Korea Neurodegenerative Disorder Therapeutics Market Overview
  • 14.2. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurodegenerative Disorder Therapeutics Market

  • 15.1. Western Europe Neurodegenerative Disorder Therapeutics Market Overview
  • 15.2. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurodegenerative Disorder Therapeutics Market

  • 16.1. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurodegenerative Disorder Therapeutics Market

  • 17.1. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurodegenerative Disorder Therapeutics Market

  • 18.1. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurodegenerative Disorder Therapeutics Market

  • 19.1. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurodegenerative Disorder Therapeutics Market

  • 20.1. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurodegenerative Disorder Therapeutics Market

  • 21.1. Eastern Europe Neurodegenerative Disorder Therapeutics Market Overview
  • 21.2. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurodegenerative Disorder Therapeutics Market

  • 22.1. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurodegenerative Disorder Therapeutics Market

  • 23.1. North America Neurodegenerative Disorder Therapeutics Market Overview
  • 23.2. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurodegenerative Disorder Therapeutics Market

  • 24.1. USA Neurodegenerative Disorder Therapeutics Market Overview
  • 24.2. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurodegenerative Disorder Therapeutics Market

  • 25.1. Canada Neurodegenerative Disorder Therapeutics Market Overview
  • 25.2. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurodegenerative Disorder Therapeutics Market

  • 26.1. South America Neurodegenerative Disorder Therapeutics Market Overview
  • 26.2. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurodegenerative Disorder Therapeutics Market

  • 27.1. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurodegenerative Disorder Therapeutics Market

  • 28.1. Middle East Neurodegenerative Disorder Therapeutics Market Overview
  • 28.2. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurodegenerative Disorder Therapeutics Market

  • 29.1. Africa Neurodegenerative Disorder Therapeutics Market Overview
  • 29.2. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Neurodegenerative Disorder Therapeutics Market Competitive Landscape
  • 30.2. Neurodegenerative Disorder Therapeutics Market Company Profiles
    • 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Neurodegenerative Disorder Therapeutics Market Other Major And Innovative Companies

  • 31.1. UCB S.A.
  • 31.2. F. Hoffmann-La Roche Ltd.
  • 31.3. ACADIA Pharmaceuticals Inc.
  • 31.4. H. Lundbeck A/S
  • 31.5. Boehringer Ingelheim International GmbH
  • 31.6. Merck Serono S.A.
  • 31.7. Orion Corporation
  • 31.8. Mitsubishi Tanabe Pharma America
  • 31.9. Allergan PLC
  • 31.10. GlaxoSmithKline PLC
  • 31.11. AbbVie Inc.
  • 31.12. Eli Lilly and Company
  • 31.13. Celgene Corporation
  • 31.14. Neuro-Hitech Inc.
  • 31.15. Bayer Schering Pharma AG

32. Global Neurodegenerative Disorder Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market

34. Recent Developments In The Neurodegenerative Disorder Therapeutics Market

35. Neurodegenerative Disorder Therapeutics Market High Potential Countries, Segments and Strategies

  • 35.1 Neurodegenerative Disorder Therapeutics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurodegenerative Disorder Therapeutics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurodegenerative Disorder Therapeutics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer